Search results
Results From The WOW.Com Content Network
Mesothelin is a 40 kDa protein that is expressed in mesothelial cells. [7] The protein was first identified by its reactivity with monoclonal antibody K1. [8] Subsequent cloning studies showed that the mesothelin gene encodes a precursor protein that is processed to yield mesothelin which is attached to the cell membrane by a glycophosphatidylinositol linkage and a 31-kDa shed fragment named ...
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. [1] It was developed by Morphotek, Inc. . Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
A new study has found that low levels of one anti-inflammatory antibody — IgM anti-PC — are also associated with atherosclerosis and heart attacks in older women, while higher levels appear to ...
In contrast, optimal (health) range or therapeutic target is a reference range or limit that is based on concentrations or levels that are associated with optimal health or minimal risk of related complications and diseases. For most substances presented, the optimal levels are the ones normally found in the population as well.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
After seroconversion, the antibody is detectable by standard techniques and remains detectable unless the individual seroreverts, in a phenomenon called seroreversion, or loss of antibody detectability, which can occur due to weakening of the immune system or decreasing antibody concentrations over time. Seroconversion refers the production of ...
Antibody testing, such as anti-Hu or collapsing response mediator protein, can aid in the identification of paraneoplastic patients. [ 1 ] One should rule out Guillain-Barré syndrome if the patient exhibits acute or subacute autonomic instability accompanied by weakness , as this condition frequently results in ileus , constipation , and blood ...
The level of soluble mesothelin-related protein is elevated in the serum of about 75% of patients at diagnosis and it has been suggested that it may be useful for screening. [70] Doctors have begun testing the Mesomark assay , which measures levels of soluble mesothelin -related proteins (SMRPs) released by mesothelioma cells.